How do we know a drug finding belongs in your report?

First, match the right asset

A drug can appear under a brand, a generic molecule, a development code, or another name. Setup begins by checking the names and records relevant to the asset you specify. A study that names tirzepatide, for example, may matter to Zepbound and Mounjaro; it is not automatically a Zepbound-only finding. When a match is uncertain, the report should show the gap instead of claiming coverage.

Then, compare the source record

Watchtower checks relevant public sources such as trial registries, FDA records, patent and generic-entry lists, CMS datasets, and SEC filings. A change is described with the field or record that moved, a date, and a link back to the source. Reports are checked by an analyst against the original records before delivery. News and social discussion can add context but are kept distinct from primary records.

See the full source directory and its coverage notes →

State whether it is brand or molecule evidence

Some facts are tied to a specific branded product or FDA application. Others, including a paper or a trial that names only the molecule, can be relevant to sibling brands. We label that level in the report and do not add one molecule-level number to each brand as if each brand owned it separately.

The Zepbound sample marks its FDA label change as brand-level and Roche’s tirzepatide comparison study as molecule-level.

Show freshness and the limits of a conclusion

A source’s publication schedule is different from the date we last checked it. Both matter. The sample report lists its source check dates and identifies unchanged records. If a source has no record for an asset, the coverage check or report says so; an empty result is not proof that no event occurred.

Source facts also have limits. A changed trial completion date is not a confirmed readout date. A Paragraph IV certification is not an approval or a generic launch date. We link the primary record so you can make the next judgment with the right evidence.

What can the free coverage check tell you?

It identifies which relevant sources have records for your named assets, where coverage is thin, and what publication cadence can be expected. It does not promise that all 36 core public sources will produce a finding for every drug. See how the watch is set up →